Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205684 | 1.00 | LMNA (0.50) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL12909848 | 1.00 | LMNA (0.50) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL6686850 | 0.95 | LMNA (0.49) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL6686852 | 0.95 | LMNA (0.49) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL10353311 | 0.94 | CNR1 (0.49) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL9511157 | 0.94 | CNR1 (0.49) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL10353701 | 0.94 | CNR1 (0.49) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL1978843 | 0.94 | CNR1 (0.49) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL1978841 | 0.94 | CNR1 (0.49) | LMNAGAACNR1DAGLATSHR | |
| SCHEMBL7715586 | 0.94 | CNR1 (0.49) | LMNAGAACNR1DAGLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119280226-A | Application of butyl pyroglutamate in preparation of anti-Alzheimer disease drugs | 江西农业大学 | 2025-01-10 | — | — | CN | claimed |
| CN-119280225-A | Application of butyl pyroglutamate in preparation of antihypertensive drugs | 江西农业大学 | 2025-01-10 | — | — | CN | claimed |
| CN-102711455-A | Biocide compositions comprising derivatives of pyroglutamic acid | COGNIS IP MAN GMBH | 2012-10-03 | — | — | CN | claimed |
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | claimed |
| EP-0397519-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1994-11-09 | — | — | EP | claimed |
| EP-0342056-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1994-08-17 | — | — | EP | claimed |
| EP-0277428-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1994-03-23 | — | — | EP | claimed |
| EP-0342055-B1 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1994-01-12 | — | — | EP | claimed |
| EP-0342054-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1993-11-03 | — | — | EP | claimed |
| US-5137714-A | Anhydrous cosmetic composition comprising stable lower alkyl esters of pyroglutamic acid | UNILEVER PATENT HOLDINGS B.V. (NL) | 1992-08-11 | — | — | US | claimed |
| EP-0397519-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1990-11-14 | — | — | EP | claimed |
| EP-0342055-A2 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0342054-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0342056-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0277428-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1988-08-10 | — | — | EP | claimed |
| US-12619006-B2 | Wavelength selective absorption filter and display device | FUJIFILM CORPORATION (JP) | 2026-05-05 | — | — | US | disclosed |
| CN-116568763-B | Wavelength selective absorption filter and display device | 富士胶片株式会社 | 2025-05-13 | — | — | CN | disclosed |
| EP-0295092-A2 | Skin treatment composition | UNILEVER PLC (GB) | 1988-12-14 | — | — | EP | disclosed |
| EP-0277428-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1988-08-10 | — | — | EP | disclosed |
| EP-0272920-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12619006-B2 | Wavelength selective absorption filter and display device | STRA6, SULT1A1, SLC7A1 | LMNA 2969/4885GAA 2501/4885CNR1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.